Public company · NasdaqPublished company research

PGNY

Identity verified against SEC EDGAR filing 0001551306-26-000020; registered as Progyny, Inc., CIK 0001551306.

Progyny

Progyny is mapped to the Women's health formalization theme as Fertility benefits platform - manages employer-sponsored fertility and family-building benefits (benefits + specialty pharmacy).. High and pure-play. Q1 2025 revenue USD 324.0 million (+16.5% YoY), fertility benefit services USD 206.4 million (+22%), 532 clients, ~900,000 lives added in the recent selling season, 16,200 ART cycles (+9%); full-year 2025 revenue guidance USD 1.185-1.235 billion. Theme materiality is stated separately and, where not independently verified, is marked accordingly.

Ask follow-up research

Reviewed company research · researched 2026-07-22 · not an individual investment recommendation

Listing: public
Ticker: PGNY
Exchange: Nasdaq
HQ: —
Currency: USD
SEC CIK: 0001551306

Investment case

How this company captures the theme economics

Competitive position

High and pure-play. Q1 2025 revenue USD 324.0 million (+16.5% YoY), fertility benefit services USD 206.4 million (+22%), 532 clients, ~900,000 lives added in the recent selling season, 16,200 ART cycles (+9%); full-year 2025 revenue guidance USD 1.185-1.235 billion. Company-specific competitive positioning is assessed at the theme level and awaits deeper primary research.

Scarce assets

Scarce assets in this value chain include reimbursement and coverage decisions (state ivf/fertility mandates, employer benefit design, cms/medicaid) - the gating variable for the whole theme., specialist capacity: reproductive endocrinologists/fertility clinics, urogynecology, maternal-fetal medicine., proprietary clinical data and validated assays/algorithms (nipt content, hpv assays, ai mammography)..

Products, segments, and customers

Progyny operates in Women's health formalization. Segment- and product-level detail is pending company-specific research.

Theme capture

Conditions

What must be true

2026 selling-season client and covered-lives adds; utilization and take-rate trends; retention; competitive response from national carriers; Q1 2026 print (not reliably retrieved this session).
The exposure described for Progyny must be confirmed as financially material in official filings.

Identifiable catalysts

Forthcoming quarterly and annual issuer filings
Theme-level catalysts detailed in the Women's health formalization brief

Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Fertility benefits platform - manages employer-sponsored fertility and family-building benefits (benefits + specialty pharmacy).

Women's health formalization

Evidence: Fetched Progyny Q1 2025 results (dated 2025-05-08 via IR/press). Directly captures the reimbursement-formalization thesis; policy tailwinds (state mandates, federal employer pathway) are supportive.
Materiality: disclosed — Pure-play fertility benefits company with disclosed revenue, client, covered-lives and cycle metrics fetched from the Q1 2025 release.

Financial evidence

Official SEC filing evidence

Reference period: FY2025.

Operating income$85 million
FY2025[1]
EBITDA$90 million
FY2025[1]
Net income to common$59 million
FY2025[1]
Diluted EPS$0.65
FY2025[1]
Operating cash flow$210 million
FY2025[1]
Free cash flow$192 million
FY2025[1]
Cash and equivalents$112 million
FY2025 year-end[1]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.

Thesis-break conditions

Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.

Investability conclusion

Where the evidence lands

Identity and filing financials are established; theme materiality is stated per the mapped theme assessment. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

2026 selling-season client and covered-lives adds; utilization and take-rate trends; retention; competitive response from national carriers; Q1 2026 print (not reliably retrieved this session).

Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

Progyny, Inc. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-27 · accessed 2026-07-22